FibroGen (NASDAQ:FGEN) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

FibroGen, Inc. (NASDAQ:FGENGet Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.46 and traded as low as $0.45. FibroGen shares last traded at $0.46, with a volume of 608,198 shares trading hands.

Analyst Ratings Changes

FGEN has been the topic of a number of research analyst reports. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th. HC Wainwright raised FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. Finally, StockNews.com assumed coverage on shares of FibroGen in a research report on Wednesday. They set a “hold” rating for the company.

Read Our Latest Stock Report on FibroGen

FibroGen Trading Down 2.6 %

The stock has a market capitalization of $46.68 million, a PE ratio of -0.38 and a beta of 0.75. The business’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.46.

FibroGen (NASDAQ:FGENGet Free Report) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the previous year, the business posted ($0.52) earnings per share. On average, analysts predict that FibroGen, Inc. will post -0.8 EPS for the current year.

Institutional Investors Weigh In On FibroGen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Franklin Street Advisors Inc. NC grew its stake in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 100,000 shares in the last quarter. Sei Investments Co. grew its stake in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in FibroGen during the 2nd quarter worth approximately $145,000. FMR LLC raised its position in shares of FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Featured Stories

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.